US5290540A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating infectious respiratory diseases
Assignee: Henry M. Jackson Foundation
•
Filing: 1992-05-01
•
Granted: 1994-03-01
•
Expires: 2012-05-01
Abstract
Abstract A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.
Inventors
- 👤 Gregory A. Prince
- 👤 Val G. Hemming
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 13:28
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61K39/40; A61K31/00; A61K31/185; A61K31/19; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/56; A61K31/57; A61K31/58; A61K31/60; A61K31/70; A61K39/42; A61P; A61P29/00; C; C07; C07K; C07K16/00; C07K16/18; C07K16/24; A61K38/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
125 words
A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by a microorganism selected from a virus, a bacterium, a fungus, and Pneumocystis carinii, comprising administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation and an anti-infectious agent with activity against said microorganism at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce the concentration of said microorganism; the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 2
Independent Claim
125 words
A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by a microorganism selected from a virus, a bacterium, a fungus, and Pneumocystis carinii, comprising administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation and an anti-infectious agent with activity against said microorganism at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce the concentration of said microorganism; the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 3
Dependent Claim
16 words
The method of claim 1, wherein the anti-infectious agent is administered topically, orally, intravenously, or intraperitoneally.
Claim 4
Dependent Claim
12 words
The method of claim 1, wherein the anti-inflammatory agent is a corticosteroid.
Claim 5
Dependent Claim
21 words
The method of claim 3, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, triamcinolone, dexamethasone, and beclamethasone.
Claim 6
Dependent Claim
12 words
The method of claim 1, wherein the anti-inflammatory agent is administered intranasally.
Claim 7
Dependent Claim
43 words
The method of claim 1, wherein the microorganism is influenza virus type A, influenza virus type B, influenza virus type C, parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, a respiratory coronavirus, or a respiratory adenovirus.
Claim 8
Dependent Claim
20 words
The method of claim 1, wherein the microorganism is parainfluenza virus type 3, respiratory syncytial virus, or adenovirus type 5.
Claim 9
Dependent Claim
15 words
The method of claim 1, wherein the anti-infectious agent is an antibody to said microorganism.
Claim 10
Dependent Claim
14 words
The method of claim 8, wherein the antibody is a polyclonal or monoclonal antibody.
Claim 11
Dependent Claim
18 words
The method of claim 1, wherein the anti-infectious agent is human immunoglobulin which comprises antibodies to said microorganism.
Claim 12
Dependent Claim
28 words
The method of claim 10, wherein said human immunoglobulin is human immunoglobulin G in a dosage of from 0.1 μg to 100 mg/kg body weight of the host.
Claim 13
Dependent Claim
17 words
The method of claim 10, wherein said microorganism is respiratory syncytial virus or parainfluenza virus type 3.
Claim 14
Dependent Claim
20 words
The method of claim 1, wherein the anti-infectious agent is an anti-bacterial agent, antifungal agent, anti-parasitic agent, or anti-viral agent.
Claim 15
Dependent Claim
22 words
The method of claim 1, wherein the anti-infectious agent is an anti-viral agent selected from the group consisting of ribavirin and amantidine.
Claim 16
Dependent Claim
11 words
The method of claim 1, wherein the host is a mammal.
Claim 17
Dependent Claim
11 words
The method of claim 1, wherein the host is a human.
Claim 18
Independent Claim
123 words
A method of treating pneumonia in a human, susceptible to or suffering from pneumonia caused by respiratory syncytial virus or parainfluenza virus type 3, comprising administering directly into the lower respiratory tract of the human an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation and an human immunoglobulin G at a dosage of from 0.1 μg to 100 mg/kg body weight of the host to reduce the concentration of the respiratory syncytial virus or parainfluenza virus type 3, the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 19
Independent Claim
123 words
A method of treating pneumonia in a human, susceptible to or suffering from pneumonia caused by respiratory syncytial virus or parainfluenza virus type 3, comprising administering directly into the lower respiratory tract of the human an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation and an human immunoglobulin G at a dosage of from 0.1 μg to 100 mg/kg body weight of the host to reduce the concentration of the respiratory syncytial virus or parainfluenza virus type 3, the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 20
Dependent Claim
12 words
The method of claim 17, wherein the anti-inflammatory agent is a corticosteroid.
Claim 21
Independent Claim
123 words
A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by parainfluenza virus type 3, adenovirus type 5, or respiratory syncytial virus, comprising administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation and an anti-infectious agent with activity against said virus at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce the concentration of said virus, the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 22
Independent Claim
123 words
A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by parainfluenza virus type 3, adenovirus type 5, or respiratory syncytial virus, comprising administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation and an anti-infectious agent with activity against said virus at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce the concentration of said virus, the anti-inflammatory agent and the anti-infectious agent being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 23
Dependent Claim
78 words
A medication that comprises aerosol particles having a size of less than 10 microns comprising an anti-infectious agent with activity against an infectious agent at a dosage of from 0.1 μg to 1000 mg/kg body weight of a host to reduce the concentration of said infectious agent and an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation.
Claim 24
Dependent Claim
78 words
A medication that comprises aerosol particles having a size of less than 10 microns comprising an anti-infectious agent with activity against an infectious agent at a dosage of from 0.1 μg to 1000 mg/kg body weight of a host to reduce the concentration of said infectious agent and an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 μg to 1000 mg/kg body weight of the host to reduce inflammation.
Claim 25
Dependent Claim
35 words
The method of claim 1 wherein the anti-inflammatory agent is administered at a dosage of 2 μg to 0.2 mg/kg and the anti-infectious agent is administered at a dosage of 2 μg to 20 mg/kg.
Claim 26
Independent Claim
124 words
A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by a microorganism selected from a virus, a bacterium, a fungus, and Pneumocystis carinii, comprising topically administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 82 g to 1000 mg/kg body weight of the host to reduce inflammation and an human immunoglobulin G at a dosage of from 0.1 μg to 100 mg/kg body weight of the host to reduce the concentration of said microorganism, the anti-inflammatory agent and the human immunoglobulin G being administered in the form of a small particle aerosol having a size less than 10 microns.
Claim 27
Independent Claim
124 words
A method of treating pneumonia in a host, susceptible to or suffering from pneumonia caused by a microorganism selected from a virus, a bacterium, a fungus, and Pneumocystis carinii, comprising topically administering directly into the lower respiratory tract of the host an anti-inflammatory agent selected from a corticosteroid, indomethacin, ibuprofen, and acetylsalicylic acid at a dosage of from 0.1 82 g to 1000 mg/kg body weight of the host to reduce inflammation and an human immunoglobulin G at a dosage of from 0.1 μg to 100 mg/kg body weight of the host to reduce the concentration of said microorganism, the anti-inflammatory agent and the human immunoglobulin G being administered in the form of a small particle aerosol having a size less than 10 microns.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-02-28 | 1997-08-30 | 1998-03-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-02-28 | 2001-08-30 | 2002-03-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-02-28 | 2005-08-30 | 2006-03-01 | $7700.00 | Window Closed / Lapsed |